ESTIMATION OF LONG‐TERM SURVIVAL WITH POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB FOR PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL). (12th June 2019) - Sehn, L.H.; Flowers, C.; McMillan, A.; Morschhauser, F.; Salles, G.; Felizzi, F.; Launonen, A.; Qayum, N.; Thuresson, P.O.